Skip to main content
logo
4D Molecular Therapeutics, Inc. (FDMT)
NASDAQ: FDMT · Real-Time Price · USD
8.48
+0.15 (1.80%)
Mar 16, 2026, 4:00 PM EDT - Market closed

4D Molecular Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Sep '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Revenue
0.120.0420.723.1318.0413.61
Revenue Growth (YoY)
605.88%-99.82%562.29%-82.65%32.52%94.85%
Gross Profit
0.120.0420.723.1318.0413.61
Selling, General & Admin
49.3246.5836.4932.9128.0117.24
Research & Development
138.09141.397.180.2561.3653.04
Total Operating Expenses
187.41187.88133.59113.1689.3770.28
Operating Income
-230.38-187.84-112.87-110.03-71.33-56.66
Interest Income
21.2427.0512.212.570.140.15
Other Non-Operating Income (Expense)
-0.02-0.08-0.18-0.04-0.12-0.18
Total Non-Operating Income (Expense)
21.2226.9712.032.540.02-0.03
Pretax Income
-209.16-160.87-100.84-107.49-71.32-56.69
Net Income
-209.18-160.87-100.84-107.49-71.32-56.69
Net Income to Common
-209.18-160.87-100.84-107.49-71.32-56.69
Shares Outstanding (Basic)
56543932286
Shares Outstanding (Diluted)
56543932286
Shares Change (YoY)
10.08%37.86%20.95%16.66%331.23%25.05%
EPS (Basic)
-3.75-2.98-2.58-3.32-2.57-8.82
EPS (Diluted)
-3.75-2.98-2.58-3.32-2.57-8.82
Free Cash Flow
-185.05-138.37-78.56-98.22-78.24-51.91
Free Cash Flow Per Share
-3.31-2.57-2.01-3.04-2.82-8.07
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Operating Margin
-191982.50%-507678.38%-544.65%-3516.52%-395.46%-416.28%
Profit Margin
-174296.67%-434778.38%-486.59%-3435.41%-395.37%-416.49%
FCF Margin
-154209.17%-373975.68%-379.11%-3139.05%-433.77%-381.35%
EBITDA
-222.95-181.14-107.12-106.15-68.31-55.22
EBITDA Margin
-185791.67%-489556.76%-516.90%-3392.52%-378.72%-405.68%
EBIT
-230.38-187.84-112.87-110.03-71.33-56.66
EBIT Margin
-191982.50%-507678.38%-544.65%-3516.52%-395.46%-416.28%
Updated Nov 10, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q